Located in the US, India and Taiwan, StemCyte has established one of the largest, most racially diverse, and highest quality cord blood stem cell banks in the world. StemCyte has supplied more than 2,000 cord blood units to treat life-threatening diseases in more than 350 transplant centers worldwide. StemCyte is actively involved in the development of new umbilical cord blood-based cell therapies and the development of trials investigating regenerative spinal cord therapies. StemCyte is one of the only for-profit companies contracted by the US Department of HHS to help contribute clinical grade cord blood units to the public National Cord Blood Inventory for unrelated transplants. Its headquarters are in Baldwin Park, California. To learn more visit www.StemCyte.com.
